TScan Q1 net loss $34.1M; cash runway into Q1 2027; registrational trial H2 2025

TScan Therapeutics, Inc.

2025-Q1 EPS reported -$0.26 revenue$2,171,000

Revenue $2.2M (up from $0.6M YoY); R&D expense $29.8M; net loss $34.1M vs $30.1M YoY.
Cash, equivalents, and marketable securities $251.7M (plus $5.0M restricted) funding operations into Q1 2027.
On track to initiate registrational trial for TSC-101 and file IND for TSC-102-A0301 in H2 2025.
First patient dosing with multiplex TCR-T therapy expected H1 2025; safety/efficacy data by year-end.
Appointed Stephen Camiolo as SVP Market Access; presenting at ASGCT and Bank of America conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.